ATE467124T1 - Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung - Google Patents

Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Info

Publication number
ATE467124T1
ATE467124T1 AT03754894T AT03754894T ATE467124T1 AT E467124 T1 ATE467124 T1 AT E467124T1 AT 03754894 T AT03754894 T AT 03754894T AT 03754894 T AT03754894 T AT 03754894T AT E467124 T1 ATE467124 T1 AT E467124T1
Authority
AT
Austria
Prior art keywords
prp
molecules interacting
sup
peptides
features
Prior art date
Application number
AT03754894T
Other languages
English (en)
Inventor
Neil Cashman
Eustache Paramithiotis
Boissiere Sylvie La
Robert Lawton
Greg Francoeur
Lisa Estey
Marc Pinard
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Application granted granted Critical
Publication of ATE467124T1 publication Critical patent/ATE467124T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2828Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03754894T 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung ATE467124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/256,538 US20040072236A1 (en) 2002-09-27 2002-09-27 PrPSc -interacting molecules and uses thereof
PCT/US2003/030273 WO2004029072A2 (en) 2002-09-27 2003-09-25 PrPsc -INTERACTING MOLECULES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE467124T1 true ATE467124T1 (de) 2010-05-15

Family

ID=32041771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754894T ATE467124T1 (de) 2002-09-27 2003-09-26 Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung

Country Status (7)

Country Link
US (2) US20040072236A1 (de)
EP (1) EP1575989B1 (de)
JP (1) JP4533750B2 (de)
AT (1) ATE467124T1 (de)
CA (1) CA2500120A1 (de)
DE (1) DE60332488D1 (de)
WO (1) WO2004029072A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US7166471B2 (en) 2001-05-31 2007-01-23 Arete Associates Misfolded protein sensor method in body fluids
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
AU2004229535A1 (en) * 2003-04-14 2004-10-28 Pathogen Removal And Diagnostic Technologies, Inc. Method for identifying ligands specific for structural isoforms of proteins
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
EP1653844B1 (de) 2003-08-13 2012-12-12 Novartis Vaccines and Diagnostics, Inc. Prion-spezifische peptid-reagenzien
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US7328063B2 (en) * 2004-11-30 2008-02-05 Cardiac Pacemakers, Inc. Method and apparatus for arrhythmia classification using atrial signal mapping
JP5162250B2 (ja) * 2005-01-13 2013-03-13 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド プリオン特異的ペプチド試薬を使用するelisaアッセイ
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
ATE528649T1 (de) * 2005-02-15 2011-10-15 Adlyfe Inc Verfahren zum nachweis falsch gefalteter proteine und prionen
KR20080048527A (ko) * 2005-09-09 2008-06-02 노파르티스 아게 프리온-특이적 펩토이드 시약
JP4769925B2 (ja) * 2006-03-15 2011-09-07 国立大学法人東北大学 異常型プリオン蛋白質の濃縮方法、および除去方法
MX2009001079A (es) * 2006-07-28 2009-02-10 Adlyfe Inc Sondas de peptido para diagnosis y terapeutica.
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
WO2008083972A2 (en) * 2007-01-12 2008-07-17 Alicon Ag Method for removing prion protein
EP2279203B1 (de) 2008-04-25 2016-06-15 University Of Saskatchewan Prionenepitope und verwendungsverfahren dafür
JP2011520108A (ja) * 2008-04-30 2011-07-14 ノバルティス アーゲー 病原性配座異性体についてのアッセイ
US20120009209A1 (en) * 2010-06-10 2012-01-12 The Regents Of The University Of California Enrichment and purification of infectious prion proteins
JP2013537971A (ja) * 2010-09-13 2013-10-07 アッヴィ・インコーポレイテッド 高感度なモノクローナル抗体残留物検出アッセイ

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0658564B1 (de) 1986-04-30 2002-01-16 Igen International, Inc. Elektrolumineszente Verbindungen und Zwischenprodukte zur Herstellung
SU1529119A1 (ru) 1987-04-20 1989-12-15 Белорусский научно-исследовательский институт эпидемиологии и микробиологии Способ определени нейровирусов в спинномозговой жидкости
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
WO1992006220A1 (en) 1990-10-05 1992-04-16 President And Fellows Of Harvard College Detection and isolation of ligands
JPH06505962A (ja) 1990-10-30 1994-07-07 ラ ホヤ キャンサー リサーチ ファウンデーション T−カドヘリン接着分子
DK0616613T3 (da) * 1991-12-03 1999-09-27 Proteus Molecular Design Fragmenter af prionprotein
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
WO1993021302A1 (en) * 1992-04-17 1993-10-28 Doheny Eye Institute Cadherin materials and methods
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5643781A (en) * 1992-12-29 1997-07-01 Doheny Eye Institute DNA encoding protocadherin-42
US5798224A (en) * 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
US5679530A (en) 1995-04-12 1997-10-21 Ludwig Institute For Cancer Research Isolated protein having molecular weight of from about 55 kilodaltons to about 65 kilodaltons (SDS-page) which binds to prion protein
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
ES2218598T3 (es) * 1995-09-14 2004-11-16 The Regents Of The University Of California Anticuerpo especifico del prpsc natural.
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
EP0914614B1 (de) * 1996-05-14 2003-09-03 Winnacker, Ernst-Ludwig, Prof. Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
CA2256312A1 (en) * 1996-05-29 1997-12-04 Mcgill University Prion protein binding proteins and uses thereof
EP0861900A1 (de) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
DE69909442T2 (de) 1998-02-20 2004-04-22 The Regents Of The University Of California, Oakland Assay für spezifische stämme von mit mehreren krankheiten zusammenhängenden proteinkonformationen
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
EP1194164B8 (de) * 1999-06-23 2007-03-21 IDEXX Laboratories Inc Prion protein peptide und deren verwendung
EP1210110A4 (de) * 1999-06-29 2003-03-19 Univ Mcgill An prionprotein bindende proteine und deren verwendungen
CA2405568A1 (en) * 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof

Also Published As

Publication number Publication date
WO2004029072A2 (en) 2004-04-08
EP1575989A2 (de) 2005-09-21
EP1575989B1 (de) 2010-05-05
DE60332488D1 (de) 2010-06-17
US7435540B2 (en) 2008-10-14
CA2500120A1 (en) 2004-04-08
WO2004029072A3 (en) 2005-12-15
EP1575989A4 (de) 2007-05-16
AU2003272695A1 (en) 2004-04-19
US20060183156A1 (en) 2006-08-17
JP2006507484A (ja) 2006-03-02
JP4533750B2 (ja) 2010-09-01
US20040072236A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE467124T1 (de) Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung
ATE541590T1 (de) Modifizierte antikörper-fragmente
DE60032486D1 (de) Prion protein peptide und deren verwendung
CY1107453T1 (el) Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
WO2005003171A3 (en) Modified antibody fragments
DE69813158T2 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
DE60224291D1 (de) System zur antikörperexpression und- synthese
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE424560T1 (de) Marker für neuromyelitis optica
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
NO20053304L (no) NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
ATE309543T1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
DE60033455D1 (de) Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
DE60332481D1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
DE60334400D1 (de) Neue polynukleotid- und polypeptidsequenzen und deren verwendungen
DE602005021322D1 (de) An calciumbindende proteine
DE60218848D1 (de) Verfahren zur trennung und/oder zum nachweis und/oder zur identifizierung und/oder zur quantifizierung von prionproteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties